Pace Life Sciences Purchases Biopharma Global
Allows CDMO’s regulatory, consulting services to further expand into the pharma market
Pace Life Sciences, LLC, a full-service contract development and manufacturing organization (CDMO) and a subsidiary of Pace, a science and technology company, has inked a deal for Biopharma Global. Biopharma specializes in full-service regulatory support for orphan products to tackle rare diseases and non-orphan products to treat indications with unmet medical needs.
The Biopharma acquisition now allows Pace to extend the following capabilities to its clients:
- Regulatory strategy development
- Regulatory affairs submissions, including FDA and EMA applications
- IND applications
- Orphan drug consulting
- Rare pediatric disease designations
- Fast track designations
- Biologics license applications
"Pace provides great value in our marketplace through our technical expertise and by meeting the strong commitments we make to our clients that rely on us to successfully advance their programs through development," says Eric Roman, Pace CEO. "The acquisition of Biopharma Global extends our reach further into regulatory strategy, guidance, and support in key therapeutic areas, and greatly extends the reach of Pace into our markets."
Biopharma will be transitioning to the Pace brand in the coming months.
Multi-Indication Drug Branding in Today’s Pharmaceutical Industry
July 2nd 2025As drug development increasingly targets multiple indications, pharma companies must make strategic branding decisions—balancing regulatory requirements, market dynamics, and patient safety—to choose between single-brand or multi-brand approaches.
